国药现代：全资子公司国药威奇达收到磷酸西格列汀化学原料药上市申请批准通知书

Core Insights - The company Guoyao Modern has received approval for the listing application of the chemical raw material drug, phosphate sitagliptin, from the National Medical Products Administration [1] Company Summary - Guoyao Modern's wholly-owned subsidiary, Guoyao Weiqida, is responsible for the development of phosphate sitagliptin, which is a DPP-4 inhibitor primarily used for improving blood sugar control in patients with type 2 diabetes [1] - The total research and development investment for the phosphate sitagliptin raw material drug has reached approximately 5.29 million yuan [1]